{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:20:00Z","timestamp":1791274800852,"version":"4.1.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2002,5]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Background and Purpose<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            It has been proposed that the novel spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate\n            <jats:italic>N<\/jats:italic>\n            -oxide (NXY-059) may be useful in the treatment of ischemic stroke. However, there is little information concerning the neuroprotective properties of NXY-059 when administered after an embolic stroke. Moreover, there is no information available concerning the combination of NXY-059 with the only Food and Drug Administration\u2013approved pharmacological agent for the treatment of acute stroke, the thrombolytic tissue plasminogen activator (tPA). Thus, we determined the effects of NXY-059G, a generic form of NXY-059, on behavioral outcome after an embolic stroke when administered alone or in combination with tPA.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Methods<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            Male New Zealand White rabbits were embolized by injecting a suspension of small blood clots into cerebral circulation via a carotid catheter. NXY-059G (100 mg\/kg) was infused intravenously 5 minutes or 3 hours after embolization, whereas control rabbits received infusions of the saline vehicle. In tPA studies, the thrombolytic was administered intravenously starting 60 minutes or 3 hours after embolization (3.3 mg\/kg). In combination studies, NXY-059G was given 5 minutes after embolization, followed by the administration of tPA beginning either 60 minutes or 3 hours after embolization. Behavioral analysis was conducted 24 hours after embolization.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Results<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            In the vehicle control group, the ES\n            <jats:sub>50<\/jats:sub>\n            value (calculated as the amount of microclots [milligrams] that produce neurological dysfunction [impairment] in 50% of the rabbits within a specific treatment group) measured 24 hours after embolism was 1.04\u00b10.31 mg, and this was increased by 153% to 2.54\u00b10.72 mg if NXY-059G was administered beginning 5 minutes after embolization. However, if NXY-059G was administered beginning 3 hours after embolization, the ES\n            <jats:sub>50<\/jats:sub>\n            was 2.01\u00b10.40 mg. The rabbits treated with tPA alone had an ES\n            <jats:sub>50<\/jats:sub>\n            of 2.64\u00b10.66 or 0.63\u00b10.35 mg if tPA administration started 60 minutes or 3 hours after embolization, respectively. If tPA was administered after NXY-059G (started at 5 minutes), the ES\n            <jats:sub>50<\/jats:sub>\n            values were 3.15\u00b10.50 or 2.66\u00b10.82 if tPA administration started 60 minutes or 3 hours after embolization, respectively.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>\n                <jats:bold>\n                  <jats:italic>Conclusions<\/jats:italic>\n                <\/jats:bold>\n                \u2014\n              <\/jats:italic>\n            <\/jats:bold>\n            This study suggests that NXY-059G is neuroprotective and can increase behavioral ratings if administered early after an embolic stroke. In addition, the study shows that NXY-059G can be used in combination with tPA without negative side effects. The drug combination can improve behavioral function and increase ES\n            <jats:sub>50<\/jats:sub>\n            values. However, during the short time course of the behavioral analysis, the combination was not statistically better than either drug alone.\n          <\/jats:p>","DOI":"10.1161\/01.str.0000015346.00054.8b","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T23:16:47Z","timestamp":1027898207000},"page":"1411-1415","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":102,"title":["Neuroprotective Effects of the Spin Trap Agent Disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate\n            <i>N<\/i>\n            -Oxide (Generic NXY-059) in a Rabbit Small Clot Embolic Stroke Model"],"prefix":"10.1161","volume":"33","author":[{"given":"Paul A.","family":"Lapchak","sequence":"first","affiliation":[{"name":"From the Department of Neuroscience, University of California at San Diego (P.A.L., D.S., J.W., J.A.Z.); VA San Diego Healthcare System (P.A.L., D.M.A., D.S., J.W., J.A.Z.); and Veterans Medical Research Foundation (P.A.L., J.A.Z.), San Diego, Calif."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia M.","family":"Araujo","sequence":"additional","affiliation":[{"name":"From the Department of Neuroscience, University of California at San Diego (P.A.L., D.S., J.W., J.A.Z.); VA San Diego Healthcare System (P.A.L., D.M.A., D.S., J.W., J.A.Z.); and Veterans Medical Research Foundation (P.A.L., J.A.Z.), San Diego, Calif."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghuan","family":"Song","sequence":"additional","affiliation":[{"name":"From the Department of Neuroscience, University of California at San Diego (P.A.L., D.S., J.W., J.A.Z.); VA San Diego Healthcare System (P.A.L., D.M.A., D.S., J.W., J.A.Z.); and Veterans Medical Research Foundation (P.A.L., J.A.Z.), San Diego, Calif."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Wei","sequence":"additional","affiliation":[{"name":"From the Department of Neuroscience, University of California at San Diego (P.A.L., D.S., J.W., J.A.Z.); VA San Diego Healthcare System (P.A.L., D.M.A., D.S., J.W., J.A.Z.); and Veterans Medical Research Foundation (P.A.L., J.A.Z.), San Diego, Calif."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Zivin","sequence":"additional","affiliation":[{"name":"From the Department of Neuroscience, University of California at San Diego (P.A.L., D.S., J.W., J.A.Z.); VA San Diego Healthcare System (P.A.L., D.M.A., D.S., J.W., J.A.Z.); and Veterans Medical Research Foundation (P.A.L., J.A.Z.), San Diego, Calif."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(01)02618-X"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004647-199907000-00009"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.32.1.190"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.2000.7364"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002210050006"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(92)90816-R"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)91689-6"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.1994.tb09816.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1988.00520260034016"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3934754"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1992.76.1.0106"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.4.815"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115110-00001"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.32.3.675"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/jo00035a020"},{"key":"e_1_3_2_16_2","unstructured":"Carney JM. 2 4-Disulfo phenyl butyl nitrone its salts and their use as pharmaceuticals. US Patent 5 780 510; 1998."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.31.12.3034"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.32.1.147"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00170-2"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/10715760100300351"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.1997.0146"},{"key":"e_1_3_2_22_2","first-page":"H1986","volume":"272","year":"1997","unstructured":"Schulz JB, Panahian N, Chen YI, Beal MF, Moskowitz MA, Rosen BR. Facilitation of postischemic reperfusion with alpha-PBN: assessment using NMR and Doppler flow techniques. Am J Physiol. 1997; 272: H1986\u2013H1995.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003643-199605000-00004"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.STR.0000015346.00054.8B","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T20:50:09Z","timestamp":1715547009000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.STR.0000015346.00054.8B"}},"subtitle":["Combination Studies With the Thrombolytic Tissue Plasminogen Activator"],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["10.1161\/01.STR.0000015346.00054.8B"],"URL":"https:\/\/doi.org\/10.1161\/01.str.0000015346.00054.8b","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5]]},"assertion":[{"value":"2001-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-02-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}